阿替普酶静脉溶栓治疗超早期脑梗死的临床效果分析

Clinical effect analysis of intravenous thrombolysis with alteplase in the treatment of ultra-early cerebral infarction

目的探究阿替普酶静脉溶栓治疗超早期脑梗死的效果。方法90例超早期脑梗死患者,随机分为对照组与实验组,每组45例。对照组给予常规治疗,实验组给予阿替普酶静脉溶栓治疗。比较两组疗效,治疗前后的美国国立卫生研究院卒中量表(NIHSS)评分,不良反应发生率。结果实验组治疗总有效率95.56%显著高于对照组的77.78%,差异具有统计学意义(P<0.05)。治疗前,两组患者的NIHSS评分比较,差异无统计学意义(P>0.05);治疗后,两组患者的NIHSS评分均较本组治疗前降低,且实验组患者的NIHSS评分(7.27±0.54)分低于对照组的(10.89±1.06)分,差异均具有统计学意义(P<0.05)。实验组不良反应发生率8.89%低于对照组的26.67%,差异具有统计学意义(P<0.05)。结论在超早期脑梗死患者中采用阿替普酶静脉溶栓治疗,能够取得满意的疗效,不良反应少,明显对患者的神经功能缺损情况进行改善,具有较高的安全性与有效性。

Objective To investigate the application effect of intravenous thrombolysis with alteplase in the treatment of ultra-early cerebral infarction.Methods A total of 90 patients with ultra-early cerebral infarction were randomly divided into control group and experimental group,with 45 cases in each group.The control group was treated with conventional treatment,and the experimental group was treated with alteplase intravenous thrombolysis.The efficacy,National Institutes of Health stroke scale(NIHSS)score before and after treatment,and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the experimental group was 95.56%,which was significantly higher than 77.78%in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in the NIHSS scores between the two groups(P>0.05).After treatment,the NIHSS scores of the two groups were lower than those of this group before treatment,and the NIHSS score(7.27±0.54)points of the experimental group was lower than(10.89±1.06)points of the control group.All the differences were statistically significant(P<0.05).The incidence of adverse reactions 8.89%in the experimental group was lower than 26.67%in the control group,and the difference was statistically significant(P<0.05).Conclusion Intravenous thrombolysis with alteplase can achieve satisfactory efficacy,significantly improve the neurological deficit of patients with less adverse reactions.It has high safety and effectiveness.